Onesource Specialty Pharma Dokumenty
Dokumenty
0
Ticker
ONESOURCE.NS
ISIN
INE013P01021
Onesource Specialty Pharma SEC Filings
Typ | Raport | Data |
|---|---|---|
| Brak dostępnych dokumentów | ||
Onesource Specialty Pharma Dokumenty 2026
Ta strona zawiera wszystkie oficjalne dokumenty i SEC filings dla akcji Onesource Specialty Pharma (ONESOURCE.NS, ISIN: INE013P01021). Obejmuje to raporty roczne (Form 10-K), raporty kwartalne (Form 10-Q) i transakcje insiderów (Form 4). Aktualnie dostępnych jest 0 dokumentów. Dane są regularnie aktualizowane, aby zapewnić inwestorom pełny przegląd regulacyjnych zgłoszeń Onesource Specialty Pharma.
Onesource Specialty Pharma Analiza akcji
Onesource Specialty Pharma Onesource Specialty Pharma Ltd operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO) within the Life Sciences Tools & Services industry. Based in Bangalore, Karnataka, the India-based company provides vertically integrated biopharma services, focusing on the development and manufacture of complex biologics, biosimilars, and vaccines. Its core offerings include prefilled syringes with or without safety devices, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. The firm supports the development of complex biologics such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and ribonucleic acid (RNA) products. The company generates revenue by catering to a variety of capsule shapes and sizes through its integrated services. These services encompass formulations ranging from traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and su. By providing comprehensive biologics solutions, the firm serves clients requiring advanced manufacturing capabilities for diverse pharmaceutical delivery systems and therapeutic modalities.